Touchlight
Touchlight is a manufacturer of high-purity, cell-free DNA using its proprietary enzymatic dbDNA technology to support the development of genetic medicines.
Touchlight has raised €107M across 2 funding rounds from 3 investors, most recently a Grant round in Dec 2022. Based in London, UK; active in Healthtech. Data as of 28 Oct 2026.
London, UKwww.touchlight.com ↗
Total raised
€107M
€106,737,256
Funding rounds
2
Investors
3
distinct backers
Active since
2021-09
latest 2022-12
Funding by year
EUR raised per yearTouchlight — funding by year — interactive chart.
Data table
| Touchlight — funding by year | |
|---|---|
| 2021 | €107M |
| 2022 | €0 |
Signals
Medium confidenceRaise-next likelihood8
base rate 45% for Grant
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Exit likelihood11
base rate 11% (2+ rounds)
- ▲ €100M+ raised
- ▲ 5y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-12-02 | Grant | — | The Bill & Melinda Gates Foundation | View deal → |
| 2021-09-20 | Other | €107M | Bridford Group,Novator | View deal → |
Related news
- Touchlight Receives Grant From Bill & Melinda Gates Foundationfinsmes.com · 2022-12
- Synthetic DNA healthtech helping the vaccine race secures $125m | Siftedsifted.eu · 2021-09
Similar companies
same sector or countryGlobal coverage: FundingData